SPDR S&P Biotech ETF Stock Forecast, Price & News

+2.24 (+1.71 %)
(As of 09/17/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume6.55 million shs
Average Volume6.11 million shs
Market Capitalization$7.30 billion
P/E RatioN/A
Dividend Yield0.23%
30 days | 90 days | 365 days | Advanced Chart
Receive XBI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer SSgA
Fund NameSPDR S&P Biotech ETF
Tax ClassificationRegulated Investment Company
Inception Date1/31/2006
Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio

Fund Focus

Asset ClassEquity
BenchmarkS&P Biotech Index
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$7.12 billion
Average Daily Volume$4.80 million

ETF Expenses

Management Fee0.35%
Other Expenses0.00%
Total Expenses0.35%
Fee Waiver0.00%
Net Expenses0.35%

Administrator, Advisor and Custodian

AdministratorSSgA Funds Management, Inc.
AdvisorSSgA Funds Management, Inc.
CustodianState Street Bank and Trust Company
DistributorState Street Global Advisors Funds Distributors, LLC
Transfer AgentState Street Bank and Trust Company
Lead Market MakerVirtu Financial

Geographic Exposure of XBI

Currency Exposure of XBI

Sector Exposure of XBI

Industry Exposure of XBI

speech bubbles
speech bubbles

SPDR S&P Biotech ETF (NYSEARCA:XBI) Frequently Asked Questions

What stocks does MarketBeat like better than SPDR S&P Biotech ETF?

Wall Street analysts have given SPDR S&P Biotech ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SPDR S&P Biotech ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has SPDR S&P Biotech ETF's stock price been impacted by COVID-19?

SPDR S&P Biotech ETF's stock was trading at $79.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XBI shares have increased by 68.7% and is now trading at $133.24.
View which stocks have been most impacted by COVID-19

Is SPDR S&P Biotech ETF a good dividend stock?

SPDR S&P Biotech ETF pays an annual dividend of $0.31 per share and currently has a dividend yield of 0.23%.
View SPDR S&P Biotech ETF's dividend history.

Who are SPDR S&P Biotech ETF's key executives?

SPDR S&P Biotech ETF's management team includes the following people:
  • James E. Ross, President, Trustee (Age 52)
  • Peter A. Ambrosini, Chief Compliance Officer (Age 69)
  • Michael P. Riley, Vice President (Age 44)
  • Gary L. French, Treasurer (Age 64)
  • John W. Clark, Assistant Treasurer (Age 46)
  • Matthew W. Flaherty, Assistant Treasurer (Age 42)
  • Chad C. Hallett, Assistant Treasurer of Street tracks series trust (Age 47)
  • Mary Moran Zeven, Secretary (Age 52)
  • Scott M. Zoltowski, Assistant Secretary (Age 44)
  • Dave Kelly, Independent Trustee

What other stocks do shareholders of SPDR S&P Biotech ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Gilead Sciences (GILD), iShares Nasdaq Biotechnology ETF (IBB), The Walt Disney (DIS), Micron Technology (MU), Cisco Systems (CSCO), AbbVie (ABBV) and Netflix (NFLX).

What is SPDR S&P Biotech ETF's stock symbol?

SPDR S&P Biotech ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI."

Who are SPDR S&P Biotech ETF's major shareholders?

SPDR S&P Biotech ETF's stock is owned by a variety of retail and institutional investors. Top institutional investors include Jefferies Group LLC (0.00%), Toronto Dominion Bank (11.63%), Toronto Dominion Bank (11.70%), JPMorgan Chase & Co. (8.30%), Morgan Stanley (7.23%) and Healthcare of Ontario Pension Plan Trust Fund (6.67%).

Which major investors are selling SPDR S&P Biotech ETF stock?

XBI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Healthcare of Ontario Pension Plan Trust Fund, JPMorgan Chase & Co., GSB Wealth Management LLC, Ikarian Capital LLC, Parallax Volatility Advisers L.P., Point72 Asset Management L.P., and Goldman Sachs Group Inc..

Which major investors are buying SPDR S&P Biotech ETF stock?

XBI stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Toronto Dominion Bank, Toronto Dominion Bank, Laurion Capital Management LP, Canada Pension Plan Investment Board, Bank of America Corp DE, Bank of America Corp DE, and Millennium Management LLC.

How do I buy shares of SPDR S&P Biotech ETF?

Shares of XBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SPDR S&P Biotech ETF's stock price today?

One share of XBI stock can currently be purchased for approximately $133.24.

How much money does SPDR S&P Biotech ETF make?

SPDR S&P Biotech ETF has a market capitalization of $7.30 billion.

What is SPDR S&P Biotech ETF's official website?

The official website for SPDR S&P Biotech ETF is www.spdrs.com.

Where are SPDR S&P Biotech ETF's headquarters?

SPDR S&P Biotech ETF is headquartered at One Lincoln Street, Boston, 02111, United States.

How can I contact SPDR S&P Biotech ETF?

SPDR S&P Biotech ETF's mailing address is One Lincoln Street, Boston, 02111, United States. The exchange traded fund can be reached via phone at +1-866-7872257.

This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.